Visceral leishmaniasis represents a serious public health concern in endemic regions and is
rapidly emerging as an opportunistic infection in HIV patients. The disease is difficult to …

Experimental vaccines to protect against visceral leishmaniasis (VL) have been developed
by using BALB/c mice infected with a large (10 7 to 10 8) inoculum of parasites. Remarkably …

This unit focuses on the murine model of cutaneous leishmaniasis and models of visceral
leishmaniasis in mice and hamsters. Each basic protocol describes the methods used to …

Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …

Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …

The leishmaniases are a group of diseases caused by different species of the protozoan
genus Leishmania and transmitted by sand fly vectors. They are a major public health …

The leishmaniases are a group of diseases caused by several pathogenic species of
Leishmania. They show a variety of clinical presentations including cutaneous (CL) …

Unlike some other parasites, Leishmania can be grown in cell-free media with ease. This
simple cultivation and the use of killed parasites as skin-test antigens (leishmanin) for …

A number of leishmaniasis vaccine candidates are at various stages of pre-clinical and
clinical development. Leishmaniasis is a vector-borne neglected tropical disease (NTD) …

We quantified Leishmania infantum parasites transmitted by natural vectors for the first time.
Both L. infantum strains studied, dermotropic CUK3 and viscerotropic IMT373, developed …